The U.K. is taking the next step in applying genomics to health care with the launch of a £105 million (US$130 million) project that will sequence the whole genomes of 100,000 healthy newborn babies to detect rare genetic conditions.

Gaush Meditech Ltd. raised HK$672 million (US$86.4 million) on a Hong Kong Stock Exchange listing. The company plans to use 38.2% of the funds to improve its research and development capability and speed up the commercialization of its patents in two years.

Chaomu Technology (Beijing) Co. Ltd. has raised nearly ¥100 million (US$14 million) in a series A+ round to develop its ophthalmic medical devices. The proceeds from the financing will be used for the clinical trials of its electromodulation product for nystagmus and the development of implantable medical chips, as well as to speed up the development of products for myopia correction. Following the financing, Beijing-based Chaomu will expand to the global market by looking for collaborations with international institutions. It plans to obtain marketing approvals for its ophthalmic medical devices in the U.S. and Europe.

3D Medicines Inc. has raised HK$408 million (US$52.5 million) in a listing on the Hong Kong Stock Exchange. Its shares opened at HK$29 apiece, jumped by more than 20% by the middle of the day, and closed at HK$31.45 on the first trading day of Dec. 15.